Spun out from the Karolinska Institute in 2013, Pelago Bioscience AB was founded to provide and develop the patented Cellular Thermal Shift Assay (CETSA®) for use in determination and quantification of drug–target interactions.
The company delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data and applications, drug discovery R&D companies are able to make better and more informed decisions at earlier stages in their projects.
This reduces time and money spent on sub optimal compounds and allows faster development of more efficacious new drugs. The company moved to purpose built laboratories at its current location in 2016 and continues to expand.
Professor Pär Nordlund
Professor Pär Nordlund, Chairman of the Board. Dept of Medical Biochemistry and Biophysics (MBB) at the Karolinska Institutet and Visiting Professor Nanyang Technical University, Singapore.
Professor Nordlund is a member of the Chemistry class of the Royal Swedish Academy of Sciences, which selects the chemistry Nobel Laureate. Professor Nordlund holds 4 patents and has more than 130 scientific publications.
He is also co-founder of the protein science company Evitra Proteoma AB and the drug discovery company Sprint Bioscience AB.
Michael Dabrowski, CEO
Michael has 15 years of Drug Discovery experience from Novo Nordisk and AstraZeneca in multiple therapeutic areas and a strong track delivery record of science, project, people and budget management.
Michael has vast experience as a project leader, manager responsible for screening and assay technology development as well as strategic disease area portfolio management and execution.
Daniel Martinez Molina, CSO
Daniel is a highly inventive and technically skilled biochemist who solved the first high resolution X-ray structure of a human membrane protein: LTC4 Synthase, enabling rational drug design in antiinflammatory projects.
After a post-doc period at Stockholm University, Daniel was recruited to MBB specifically to develop the CETSA-method for patenting and basic science research.
Eirik Refstie is an angel investor in Pelago Bioscience and Managing Director of the Singapore based Asian focused energy consultancy Buviktind Private Limited
Eirik graduated from the Norwegian University of Science and Technology in Trondheim with a MSc in mechanical engineering in 2002.
After graduation Eirik joined Schlumberger as a field engineering and has since worked for private equity and venture capital owned technology focused companies within the petroleum industry focusing on business development. Eirik is a Norwegian national based in Singapore.